



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

W. James JACKSON *et al.*

Appl. No.: 10/766,711

Filed: January 27, 2004

For: **Chlamydia Protein, Sequence and
Uses Thereof**

Confirmation No.: 4900

Art Unit: 1645

Examiner: BASKAR, Padmavathi

Atty. Docket: 2479.0040003/EJH/C-K

**First Supplemental Information Disclosure Statement
Under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents **FP1** and **NPL1 to NPL32** are submitted. In accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents **US1** to **US9**, cited on the attached Form, PTO/SB/08A, are not submitted.

The Examiner's attention is directed to the following U.S. Patents and co-pending U.S. Patent Applications, which are directed to related technical subject matter:

Application No. 09/612,402, inventors Jackson, W.J., *et al.*, filed July 06, 2000, issued November 04, 2003 as U.S. Patent No. 6,642,023, listed as **US5**;

Application No. 09/542,520, inventors Jackson, W.J., *et al.*, filed April 03, 2000, issued May 03, 2005 as U.S. Patent No. 6,887,843, listed as **US6**;

Application No. 10/701,844, inventors Jackson, W.J., *et al.*, filed November 04, 2003, published on April 8, 2004 as U.S. Publication No. 2004/0067524 A1, listed as **US8**.

Application No. 10/931,779, inventors Jackson, W.J., *et al.*, filed September 1, 2004, published on March 3, 2005 as U.S. Publication No. 2005/0048557 A1; listed as **US9**;

Application No. 08/942,596, inventors Jackson, W.J., *et al.*, filed October 2, 1997, not published; listed as **NPL31**.

The identification of these U.S. Patent Applications is not to be construed as a waiver of secrecy as to these applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Elizabeth J. Haanes, Ph.D.
Attorney for Applicants
Registration No. 42,613

Date: November 17, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

603747_1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/766,711
				Filing Date	January 27, 2004
				First Named Inventor	W. James JACKSON
				Art Unit	1645
				Examiner Name	BASKAR, Padmavathi
Sheet	1	of	4	Attorney Docket Number	2479.0040003/EJH/C-K

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	AMERSDORFER, P., <i>et al.</i> , "Molecular Characterization of Murine Humoral Immune Response to Botulinum Neurotoxin Type A Binding Domain as Assessed by Using Phage Antibody Libraries," <i>Infect. Immun.</i> 65:3743-3752, American Society For Microbiology (September 1997)	
	NPL2	BARENKAMP, S.J., and ST. GEME III, J.W., "Identification of Surface-Exposed B-Cell Epitopes on High-Molecular-Weight Adhesion Proteins of Nontypeable <i>Haemophilus influenzae</i> ," <i>Infect. Immun.</i> 64:3032-3037, American Society For Microbiology (August 1996)	
	NPL3	BATTEIGER, B.E., <i>et al.</i> , "Species-, Serogroup-, and Serovar-Specific Epitopes Are Juxtaposed in Variable Sequence Region 4 of the Major Outer Membrane Proteins of Some <i>Chlamydia trachomatis</i> Serovars," <i>Infect. Immun.</i> 64:2839-2841, American Society For Microbiology (July 1996)	
	NPL4	BAUGHN, R.E., <i>et al.</i> , "Epitope Mapping of B-Cell Determinants on the 15-Kilodalton Lipoprotein of <i>Treponema pallidum</i> (Tpp15) with Synthetic Peptides," <i>Infect. Immun.</i> 64:2457-2466, American Society For Microbiology (July 1996)	
	NPL5	BROWN, D.R., <i>et al.</i> , "Identification and Characterization of a Neutralizing Monoclonal Antibody Against Botulinum Neurotoxin, Serotype F, Following Vaccination With Active Toxin," <i>Hybridoma</i> 16:447-456, Mary Ann Leibert, Inc. (October 1997)	
	NPL6	BURNIE, J.P., <i>et al.</i> , "Defining Antibody Targets in <i>Streptococcus oralis</i> Infection," <i>Infect. Immun.</i> 64:1600-1608, American Society For Microbiology (May 1996)	
	NPL7	CHOH, H.L., <i>et al.</i> , "β-Endorphin omission analogs: dissociation of immunoreactivity from other biological activities," <i>Proc. Natl. Acad. Sci. USA</i> 77:3211-3214, National Academy of Sciences (1980)	
	NPL8	CUNNINGHAM, M.W., <i>et al.</i> , "Molecular Analysis of Human Cardiac Myosin-Cross-Reactive B- and T-Cell Epitopes of the Group A Streptococcal M5 Protein," <i>Infect. Immun.</i> 65:3913-3923, American Society For Microbiology (September 1997)	
	NPL9	DAVIES, D.R., and Cohen, G.H., "Interactions of protein antigens with antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 93:7-12, National Academy of Sciences (January 1996)	
	NPL10	DE SA, C., "La protéine majeure de la membrane externe de <i>Chlamydia</i> : structure et fonctions," <i>Vet. Res.</i> 27:317-331, ZDP Sciences (February 1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/766,711
				Filing Date	January 27, 2004
				First Named Inventor	W. James JACKSON
				Art Unit	1645
				Examiner Name	BASKAR, Padmavathi
Sheet	2	of	4	Attorney Docket Number	2479.0040003/EJH/C-K

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL11	DELVIG, A.A., <i>et al.</i> , "Immune responses to linear epitopes on the PorB protein of <i>Neisseria meningitidis</i> in patients with systemic meningococcal disease," <i>Microbiology</i> 142:2491-2498, Society for General Microbiology (September 1996)	
	NPL12	DUIM, B., <i>et al.</i> , "Fine Mapping of Outer Membrane Protein P2 Antigenic Sites Which Vary During Persistent Infection by <i>Haemophilus influenzae</i> ," <i>Infect. Immun.</i> 64:4673-4679, American Society For Microbiology (November 1996)	
	NPL13	FAN, J., and Stephens, R.S., "Antigen Conformation Dependence of <i>Chlamydia trachomatis</i> Infectivity Neutralization," <i>J. Infect. Dis.</i> 176:713-721, University of Chicago Press (September 1997)	
	NPL14	GHADJARI, A., <i>et al.</i> , "Epitope mapping <i>Candida albicans</i> proteinase (SAP 2)," <i>FEMS Immunol. Med. Microbiol.</i> 19:115-123, Elsevier Science (October 1997)	
	NPL15	GOODMAN, J.W., "Immunogenicity & Antigenicity," in <i>Basic and Clinical Immunol.</i> , Stites, D.P., <i>et al.</i> , eds., Appleton & Lange, Norwalk, CT, pp. 102-108 (1991)	
	NPL16	JANEWAY, C., <i>et al.</i> , <i>Immunogenicity</i> , John Wiley & Sons, Inc., New York, NY, pp. 65-71 (1989)	
	NPL17	LAINSON, F.A., <i>et al.</i> , "Characterization of epitopes involved in the neutralization of <i>Pasteurella haemolytica</i> serotype A1 leukotoxin," <i>Microbiology</i> 142:2499-2507, Society for General Microbiology (September 1996)	
	NPL18	MÉCHIN, M., <i>et al.</i> , "Identification of Surface-Exposed Linear B-Cell Epitopes of the Nonfimbrial Adhesin CS31A of <i>Escherichia coli</i> by Using Overlapping Peptides and Antipeptide Antibodies," <i>Infect. Immun.</i> 64:3555-3564, American Society for Microbiology (September 1996)	
	NPL19	MORRIS, G.E., <i>Epitope Mapping Protocols</i> , Morris, G.E., ed., Humana Press, Inc., Totowa, NJ, 5 pages (1996)	
	NPL20	OETTINGER, T., <i>et al.</i> , "Characterization of the Delayed Type Hypersensitivity-Inducing Epitope of MPT64 from <i>Mycobacterium tuberculosis</i> ," <i>Scand. J. Immunol.</i> 45:499-503, Blackwell Science, Ltd. (May 1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/766,711
				Filing Date	January 27, 2004
				First Named Inventor	W. James JACKSON
				Art Unit	1645
				Examiner Name	BASKAR, Padmavathi
Sheet	3	of	4	Attorney Docket Number	2479.0040003/EJH/C-K

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL21	PAL, S., <i>et al.</i> , "Monoclonal immunoglobulin A antibody to the major outer membrane protein of <i>Chlamydia trachomatis</i> mouse pneumonitis biovar protects mice against a genital chlamydial challenge," <i>Vaccine</i> 15:575-582, Elsevier Science (April 1997)	
	NPL22	READ, T.D., <i>et al.</i> , "Genome sequence of <i>Chlamydophila caviae</i> (<i>Chlamydia psittaci</i> GPIC): examining the role of niche-specific genes in the evolution of the Chlamydiaceae," <i>Nucleic Acids Res.</i> 31:2134-2147, Oxford University Press (April 2003)	
	NPL23	ROITTE, I., <i>et al.</i> , <i>Immunology</i> , Roitt, I., <i>et al.</i> , eds., St. Louis, MO, CV. Mosby, pp. 7.1-7.10 (1989)	
	NPL24	SAINT-REMY, J.R., "Epitope mapping: a new method for biological evaluation and immunotoxicology," <i>Toxicology</i> 119:77-81, Elsevier Science (April 1997)	
	NPL25	TAKAHASHI, I., <i>et al.</i> , "Epitope Maps of the <i>Escherichia coli</i> Heat-Labile Toxin B Subunit for Development of a Synthetic Oral Vaccine," <i>Infect. Immun.</i> 64:1290-1298, American Society for Microbiology (April 1996)	
	NPL26	WOOD, A.C., <i>et al.</i> , "Identification of antigenic sites on staphylococcal enterotoxin B and toxoid," <i>FEMS Immunol. Med. Microbiol.</i> 17:1-10, Elsevier Science (January 1997)	
	NPL27	YANAGISAWA, S., <i>et al.</i> , "Mapping of V β 11 ⁺ helper T cell epitopes on mycobacterial antigen in mouse primed with <i>Mycobacterium tuberculosis</i> ," <i>Int. Immunol.</i> 9:227-237, Oxford University Press (February 1997)	
	NPL28	ZHAO, Q., <i>et al.</i> , "Recall of Original Serologic Response after Challenge with Homologous and Heterologous <i>Chlamydia trachomatis</i> Serovars," <i>J. Infect. Dis.</i> 173:609-618, The University of Chicago Press (March 1996)	
	NPL29	ZHONG, G., <i>et al.</i> , "Antibody Recognition of a Neutralization Epitope on the Major Outer Membrane Protein of <i>Chlamydia trachomatis</i> ," <i>Infect. Immun.</i> 62:1576-1583, American Society for Microbiology (May 1994)	
	NPL30	ZHU, Y., <i>et al.</i> , "Identification of a <i>Coccidioides immitis</i> Antigen 2 Domain That Expresses B-Cell-Reactive Epitopes," <i>Infect. Immun.</i> 65:3376-3380, American Society for Microbiology (August 1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/766,711
				Filing Date	January 27, 2004
				First Named Inventor	W. James JACKSON
				Art Unit	1645
				Examiner Name	BASKAR, Padmavathi
Sheet	4	of	4	Attorney Docket Number	2479.0040003/EJH/C-K

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL31	Copy of co-pending U.S. Application No. 08/942,596, inventors Jackson, W.J., <i>et al.</i> , filed October 2, 1997 (NOT PUBLISHED)	
	NPL32	NCBI Entrez, GenBank Report, Accession No. R91549, Hillier, L., <i>et al.</i> (1995)	

603656_1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.